Translate page with Google

Story Publication logo November 2, 2017

United States Blocks Iran from Fusion Megaproject


Media file: p1100658.jpg

During the Iran-Iraq War in the 1980s, chemical weapons killed or sickened tens of thousands of...

Preparing for future ties, an ITER team visits an Iranian fusion facility. Image courtesy ITER Organization. Iran, 2017.
Preparing for future ties, an ITER team visits an Iranian fusion facility. Image courtesy ITER Organization. Iran, 2017.

TEHRAN—The Iran nuclear deal was meant to usher in a new era of science cooperation between the Islamic republic and other parties to the landmark agreement, which deters the country from pursuing nuclear weapons in exchange for sanctions relief. But nearly 2 years after implementation began, few projects are underway. And Science has learned that the United States has frozen Iran out of a collaboration that the deal expressly brokered: ITER, the multibillion-dollar fusion experiment in France.

Iran has been poised for months to ink an agreement to join ITER in a limited capacity. "It was all moving well, until President [Donald] Trump took office," says Ali Akbar Salehi, president of the Atomic Energy Organization of Iran here. An ITER official who requested anonymity because of the matter's sensitivity confirms that the United States is blocking Iran through its seat on ITER's governing council, which must approve Iran's participation unanimously. Bringing Iran into ITER was expected to be straightforward. The long delay, European and Iranian officials say, casts a pall on other scientific collaborations expected under the nuclear deal. An ITER council meeting later this month is expected to take up the issue.

To prevent Iran from developing nuclear weapons, the Joint Comprehensive Plan of Action (JCPOA), as the agreement is formally known, curtails Iran's uranium enrichment program and mandates the redesign of the Arak research reactor to greatly reduce plutonium production there. Last month, Trump declared that the JCPOA is not in the United States's national interest; his decertification gave the U.S. Congress 60 days to reevaluate it.

During this period, legislators could reimpose sanctions, or Congress could direct the Trump administration to renegotiate aspects of the JCPOA. That's a nonstarter, Salehi says. "There will be no more negotiations. That's it." Officials in the European Union, also a party to the deal, have said the same. Earlier this week, Richard Garwin, chief designer of the first hydrogen bomb and now an outspoken advocate of nonproliferation, along with more than 90 other prominent U.S. scientists, appealed to Congress to "act to ensure that the United States remains a party to the agreement." (Rush Holt, CEO of AAAS, which publishes Science, also signed.)

The JCPOA calls for science cooperation between Iran and the other parties: China, France, Germany, Russia, the United Kingdom, the United States, and the European Union (EU). Some joint research is slated to occur at the Fordow Fuel Enrichment Plant south of here. Fordow has two wings, each a roughly 15-meter-wide tunnel. "You're constrained by the dimensions of the place," Salehi says. In one wing, Iran is spinning centrifuges to enrich uranium until it contains at most 3.67% of the fissile U-235 isotope, the agreed limit. Iran is working with Russia to configure other centrifuges, now idle, to produce stable isotopes useful in medicine. "Progress is good, but there is still a long way to go," Salehi says.

In the other wing, the JCPOA specifies housing a nuclear, physics, and technology center. Iran has floated the idea of a "multipurpose" lab with instrumentation for unspecified types of nuclear analyses. But none of the JCPOA parties are rushing to build up science capacity at Fordow. "We want something at Fordow that would promote international scientific cooperation, which increases transparency and openness," explains one European official. But he wants to ensure that the facility would not allow Iran to develop techniques useful for evading inspections or sanctions. For Iran, setting up the lab is simply not a priority right now, Salehi says. It would be costly and, he says, "We are so busy with keeping the integrity of the JCPOA in the first place."

An easier sell is ensuring that Iran is au courant on nuclear safety, including measures for operating its Bushehr Nuclear Power Plant and handling radioactive material and waste. "It's better to start with something no one can object to," the European official says. Salehi says the EU intends to allocate €20 million to build a center of excellence in nuclear safety in Iran. The European official hedged on the funding level; the first step, he says, is to "bring Iran up to speed on safety conventions." The two sides hope to make progress at a workshop in Isfahan, Iran, this month.

A few other collaborations with Europe are in the works. The Iranian Light Source Facility, a synchrotron under construction here, will build a beamline and experimental station at the Elettra synchrotron in Trieste, Italy. Some two dozen Iranian scientists and engineers will train there, and the beamline will be shipped to Iran when its synchrotron is completed. And Iran is in early talks on possible participation in the Joint European Torus, a fusion experiment in Culham, U.K., and the planned Facility for Antiproton and Ion Research in Darmstadt, Germany.

But Iran's aspirations to join ITER hang in the balance. Iran wants to train doctoral students at ITER, and scientists here would study plasmas on the project's behalf. The country's ITER representative, plasma physicist Mahmood Ghoranneviss, says Iran hopes its limited involvement would, in a few years, blossom into full membership—a step that would infuse considerable cash into the experiment. The delay is frustrating, Ghoranneviss says. "In fusion, there are no secrets. But in our case, science and politics are mixing."


war and conflict reporting


War and Conflict

War and Conflict

Support our work

Your support ensures great journalism and education on underreported and systemic global issues